Apellis Pharmaceuticals logo
Apellis Pharmaceuticals APLS
$ 33.78 1.93%

Quarterly report 2024-Q3
added 11-05-2024

report update icon

Apellis Pharmaceuticals Income Statement 2011-2024 | APLS

Annual Income Statement Apellis Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

8.28 B 6.45 B 3.4 B 3.33 B 2.58 B 738 M 253 M - - - - - -

Shares

119 M 106 M 84.4 M 75.2 M 62.2 M 54.4 M 13.9 M - - - - - -

Historical Prices

69.7 60.8 40.3 44.3 41.1 14 16.6 - - - - - -

Net Income

-529 M -652 M -746 M -345 M -305 M -128 M -51 M -27.1 M -46.5 M -10.8 M -3.96 M - -

Revenue

397 M 75.4 M 66.6 M 251 M - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - -

Operating Income

-517 M -595 M -536 M -214 M -288 M -128 M -50.8 M -27.3 M -46.6 M - - - -

Interest Expense

-727 K -288 K 1.36 M -501 K -175 K -25 K -142 K 22.4 K - - - - -

EBITDA

-515 M -593 M -535 M -213 M -288 M -125 M -50.8 M -27.3 M 6.4 M -11.3 M -4.02 M - -

Operating Expenses

914 M 670 M 603 M 464 M 288 M 128 M 50.8 M - - - - - -

General and Administrative Expenses

501 M 277 M 177 M 139 M 67 M 22.6 M 10.5 M 4.3 M 6.36 M 2.91 M 1.71 M - -

All numbers in USD currency

Quarterly Income Statement Apellis Pharmaceuticals

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

124 M 124 M 123 K 120 M 120 M 119 M 114 K 111 M 109 K 107 K 98.1 K 97.5 M 85.7 K 80.7 K 79.2 M 76.1 M 75.6 M 75.6 M 73.7 M 63.9 M 63.8 K 63.3 K 57.9 K 56.3 M 56.2 M 54.7 M 50.4 M 50.3 M 8.44 M 8.43 M 8.43 M 8.43 M 8.43 M - - - - - - - - - - - - - - - - - - - - - -

Net Income

-57.4 M -37.7 M -66.4 M - -140 M -122 M -178 M - -191 M -156 M -139 M - -196 M -219 M -184 M 78.3 M -136 M -119 M -169 M -113 M -69.8 M -71.1 M -50.6 M -36.5 M -36 M -33.3 M -21.7 M -18.3 M -11.6 M -12.1 M -9.05 M -6.62 M -7.21 M -7.29 M -6 M - - - - - - - - - - - - - - - - - - - -

Revenue

197 M 200 M 172 M - 110 M 95 M 44.8 M - 22.1 M 16.3 M 14.4 M - 5.65 M 623 K - - 646 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-47.3 M -29.4 M -62.1 M - -137 M -120 M -175 M - -153 M -149 M -129 M - -128 M -194 M -125 M 130 M -130 M -116 M -98.8 M -106 M -69.9 M -63.5 M -48.7 M -37.2 M -35.8 M -33.5 M -21.4 M -18 M -11.6 M -12.1 M -9.05 M -6.25 M -7.23 M -7.57 M -6.23 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

70 K 24 K -499 K - -603 K -63 K -277 K - 99 K 149 K -289 K - -117 K -61 K 1.54 M - -16 K 5 K 14 K - -61 K 228 K -253 K - -22.2 K -32.9 K -31.5 K - -801 397 - - 23.6 K - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -61.6 M - - - -175 M - -152 M -148 M -129 M - -127 M -194 M -124 M 130 M -129 M -115 M -98.7 M -106 M -69.8 M -63.4 M -48.6 M -37.2 M -35.8 M -33.5 M -21.4 M -18 M -11.6 M -12.1 M -9.05 M -6.25 M -7.23 M -7.57 M -6.23 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

244 M 229 M 234 M - 247 M 215 M 220 M - 175 M 165 M 143 M - 134 M 195 M 125 M - 130 M 116 M - - 69.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

122 M 128 M 130 M - 146 M 111 M 102 M - 78.4 M 63.2 M 51.2 M - 45.8 M 49 M 40.6 M - 37 M 28.4 M 29.5 M - 18.6 M 12.8 M 8.17 M - 6.27 M 5.95 M 4.04 M - 2.07 M 1.71 M 1.82 M - 1 M - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency